Status:
COMPLETED
Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension
Lead Sponsor:
Hebei Medical University
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
Up to 80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with an ACE inhibitor (captopril) and a beta-blocker (carvedilol) is effective in ...
Detailed Description
The pathogenesis of PAH involves multiple mechanisms. However, three common factors are thought to cause the increased pulmonary vascular resistance that characterizes this devastating disease: vasoco...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A mean pulmonary artery pressure higher than 25 mm Hg or, when estimated by echocardiography, pulmonary artery pressure more than half the systemic artery pressure
- Congenital systemic-to-pulmonary shunts
Exclusion
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00240656
Start Date
October 1 2005
End Date
May 1 2006
Last Update
June 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050031